GlassScriptPhysician profile
Sunil Bharwani
NPI 1699967877
$3,644.54
in general payments reported to CMS, 2019-2025
34 companies · $50.21 in 2025
The $50.21 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $429 · 2021: $1,239 · 2022: $390 · 2023: $238 · 2024: $460 · 2025: $50.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.83 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $502.93 | 2019-2024 | Arexvy, Shingrix |
| Novo Nordisk INC | $403.71 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $325.31 | 2019-2024 | Mounjaro, Amyvid, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $211.91 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $193.50 | 2019-2023 | Farxiga |
| Amgen INC. | $180.22 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $113.08 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.32 | 2019-2021 | |
| Organogenesis INC. | $100.30 | 2019 | |
| Merck Sharp & Dohme LLC | $94.38 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.27 | 2019-2024 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $79.97 | 2019-2020 | |
| Amarin Pharma, INC. | $75.64 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $59.64 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.90 | 2023-2025 | |
| Astellas Pharma US INC | $55.30 | 2024 | Veozah |
| Abbott Laboratories | $50.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $49.23 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.12 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $27.28 | 2021 | |
| Boston Scientific Corporation | $25.15 | 2024 | Watchman Flx |
| Supernus Pharmaceuticals, INC. | $22.66 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $21.39 | 2023 | Inpefa |
| Evoke Pharma, INC. | $20.34 | 2022 | |
| Shield Therapeutics INC | $16.66 | 2023 | Accrufer |
| Jazz Pharmaceuticals INC. | $15.54 | 2021 | |
| Esperion Therapeutics, INC. | $14.09 | 2021 | |
| Exact Sciences Corporation | $13.50 | 2024 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $13.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2021 | |
| Eisai INC. | $12.57 | 2021 | |
| Allergan, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Bharwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.